## Secondary Hyperparathyroidism (SHPT)

### Causes
- **Chronic Kidney Disease (CKD)**
- **Malabsorption Syndromes**
- **Inadequate Sunlight Exposure**

### Complications
- Significant skeletal and cardiovascular issues if untreated.

### Diagnosis
- Clinical features vary based on underlying metabolic derangement.
  
#### Common Symptoms in CKD
- Skin discolouration and bruising
- Pruritus
- Lung rales 
- Pericardial rub
- Oedema
- Fatigue
- Nausea
- Poor concentration/memory 

#### Symptoms of Severe Vitamin D Deficiency and Hypocalcaemia
- Numbness and paraesthesia
- Muscle cramps, laryngospasm, tetany, seizures
- **Chvostek’s Sign:** Twitching around the mouth when tapping the face
- **Trousseau’s Sign:** Wrist flexion and finger hyperextension with blood pressure cuff inflation
- Rachitic deformities in children (e.g., bowed legs)
- Muscle weakness or pain in adults

#### Malabsorption Causes
- Crohn’s disease
- Coeliac disease
- Chronic pancreatitis 
- Whipple’s disease
- Post-gastric bypass surgery

#### Inadequate Sunlight Exposure Factors
- Elderly, housebound individuals
- High use of sun cream
- Wearing covering clothing
- Reduced skin capacity for vitamin D synthesis
- Certain medications (e.g., Phenytoin, Phenobarbital)

### Investigations
- **1st Line Tests:**
  - Serum Calcium (<2.1mmol/L indicates hypocalcaemia)
  - Serum Parathyroid Hormone (>88nanograms/L confirms hyperparathyroidism)
  - Serum Creatinine (eGFR <60mL/min/1.73m² may indicate CKD)
  - 25-Hydroxyvitamin D (levels <75nanomol/L indicate insufficiency)

#### Imaging (Post-Diagnosis)
- Ultrasound
- High-resolution contrast CT
- MRI
- 99Tc-sestamibi nuclear medicine scans

### Management (Prescribing)
- Focus on managing the underlying condition.

#### CKD Stage 3 or 4 (PTH 70-300ng/L)
- **1st Line:** Phosphate binder (sevelamer, lanthanum, calcium acetate)
- **Low Vitamin D:** Vitamin D supplement (ergocalciferol)
- **Normal 25-hydroxyvitamin D:** Vitamin D sterols (calcitriol, doxercalciferol, paricalcitol)
- **Hypercalcaemia:** Calcium-based phosphate binder 
- **Hypocalcaemia:** Calcium salt (calcium carbonate, calcium gluconate)

#### CKD Stage 5 (PTH 300-800ng/L)
- **1st Line:** Vitamin D sterol (calcitriol)
- **2nd Line:** Doxercalciferol or paricalcitol
- **Adjunct:** Calcimimetic therapy (cinacalcet, etelcalcetide)

#### Lack of Sunlight
- **1st Line:** Vitamin D supplement and calcium salt (ergocalciferol and calcium carbonate)

#### Malabsorption
- **1st Line:** Optimized management of current disease
- **Adjunct:** Vitamin D supplement (ergocalciferol) and calcium salt (calcium carbonate)

### Management (Non-Prescribing)
- **CKD Stage 3 or 4:** Dietary phosphate restriction
- **CKD Stage 5:** Subtotal or total parathyroidectomy with tissue auto-transplantation

#### Sunlight Deficiency
- **1st Line:** UV radiation exposure (5 to 15 minutes/day)

### References
- [BMJ Best Practice - SHPT](https://bestpractice.bmj.com/topics/en-gb/1107)